If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
In April 2015, Hardee's announced the opening of its 300th restaurant in the Middle East with longtime franchisee, The Americana Group. In 2015, Nation's Restaurant News ranked Hardee's as the No. 28 foodservice chain by sales in the United States through 2011. Carl's Jr. was ranked at No. 37. Combined sales would rank the two at No. 15. In 2013, QSR listed Hardee's at No. 20 and Carl's Jr. at No. 24; if combined they would have been listed at No. 14. In July 2015, Hardee's announced that it would be offering The All-Natural Burger, which launched at sister-chain Carl's Jr. restaurants in December 2014. As of March 2016, CKE has a total of 3,664 franchised or company-operated restaurants in 44 states and 37 foreign countries and U.S. territories. The Hardee's in Millvale, Pennsylvania closed suddenly on August 25, 2025, after 52 years, marking the withdrawal of Hardee's from Greater Pittsburgh. Hardee's, which had entered Pennsylvania with the Sandy's purchase a year before the Millvale location opened, retains one location in Western Pennsylvania in Waynesburg (near the West Virginia border) while the rest in Pennsylvania are in South Central Pennsylvania. In 2026, Hardee's franchise operator Boddie-Noell announced that a location in Virginia Beach would close and be converted to a concept called Biscuits & Bird that focused on breakfast biscuits and chicken tenders, with the restaurant opening under the new branding in July 2026. On July 9, 2026, Superior Star LLC, a Phoenix-based Hardee's franchisee operating in the Midwest, filed for Chapter 11 bankruptcy protection.
Rose Pharma is a private company that was founded in 2003 as Gastrotech Pharma and is located in Copenhagen, Denmark. The company is led by CEO Leif Helth Jensen, who is, together with Michael Forer and Florian Schönharting, also member of the Board of Directors. Rose Pharma is a clinical stage biotechnology company focused on the development of novel treatments for IBS and anorexia/cachexia associated with cancer and other major pathologies.
The neuroendocrine system is an integrated system composed of neurons, glands and non-endocrine tissues, and the hormones and neurochemicals they produce and receive collectively regulate physiological or behavioral state.
Sources: en.wikipedia.org
However, several species of bacteria are pathogenic and cause infectious diseases, including cholera, syphilis, anthrax, leprosy, tuberculosis, tetanus and bubonic plague. The most common fatal bacterial diseases are respiratory infections. Antibiotics are used to treat bacterial infections and are also used in farming, making antibiotic resistance a growing problem. Bacteria are important in sewage treatment and the breakdown of oil spills, the production of cheese and yogurt through fermentation, the recovery of gold, palladium, copper and other metals in the mining sector (biomining, bioleaching), as well as in biotechnology, and the manufacture of antibiotics and other chemicals. Once regarded as plants constituting the class Schizomycetes ("fission fungi"), bacteria are now classified as prokaryotes. Unlike cells of animals and other eukaryotes, bacterial cells contain circular chromosomes, do not contain a nucleus and rarely harbour membrane-bound organelles. Although the term bacteria traditionally included all prokaryotes, the scientific classification changed after the discovery in the 1990s that prokaryotes consist of two very different groups of organisms that evolved from an ancient common ancestor. These evolutionary domains are called Bacteria and Archaea. Unlike Archaea, bacteria contain ester-linked lipids in the cell membrane, possess elongation factors that are resistant to ADP-ribosylation by diphtheria toxin, use formylmethionine in protein synthesis initiation, and have numerous genetic differences, including a different 16S rRNA.
The experiences reported by women living with HIV suggest that stigma and discrimination within healthcare settings plays a large role in coercive and forced sterilization. These women are particularly vulnerable when accessing maternal health services.
=== Se–So === Michael Sela (1924–2022). Israeli immunologist at the Weizmann Institute, who worked on synthetic antigens, molecules that trigger the immune system to attack. Foreign associate Natl. Acad. Sci. USA. Nathan Sharon (1925–2011). Israeli biochemist at the Weizmann Institute of Science, expert on carbohydrates and glycoproteins. Member of the Israel Academy of Sciences and Humanities. Anatoly Sharpenak (1895–1969). Russian biochemist at the Russian Academy of Medical Sciences, who studied protein metabolism, and the aetiology and pathogenesis of dental caries. Sofia Simmonds (1917–2007). American biochemist at Yale known for work on amino acid and peptide metabolism. Karl Slotta (1895–1987). German-American biochemist at the University of Miami who discovered progesterone and studied snake venoms. Emil L. Smith (1911–2009). American protein chemist at UCLA, known in particular for studies of protein evolution. Member Natl. Acad. Sci. USA. Michael Smith (1932–2000), Canadian biochemist at the University of Wisconsin–Madison. Nobel Prize in Chemistry for developing site-directed mutagenesis Oliver Smithies FRS (foreign associate) (1925–2017). British-American geneticist and physical biochemist at the University of North Carolina at Chapel Hill who introduced starch as a medium for gel electrophoresis. Nobel Prize in Physiology or Medicine in 2007. Liz Specht (21st century). American research scientist specializing in chemical engineering and synthetic biology Alberto Sols (1917–1989). Spanish biochemist at the Spanish National Research Council.
=== Celebrations and anniversaries === On 21 November 1989, Crosby, Stills & Nash performed the song "Chippin' Away" from Graham Nash's 1986 solo album Innocent Eyes in front of the Brandenburg Gate. On 25 December 1989, Leonard Bernstein gave a concert in Berlin celebrating the end of the Wall, including Beethoven's 9th symphony (Ode to Joy) with the word "Joy" (Freude) changed to "Freedom" (Freiheit) in the lyrics sung. The poet Schiller may have originally written "Freedom" and changed it to "Joy" out of fear. The orchestra and choir were drawn from both East and West Germany, as well as the United Kingdom, France, the Soviet Union, and the United States. On New Year's Eve 1989, David Hasselhoff performed his song "Looking for Freedom" while standing atop the partly demolished Wall in front of 200,000 people. Roger Waters performed the Pink Floyd album The Wall just north of Potsdamer Platz on 21 July 1990, with guests including Scorpions, Bryan Adams, Sinéad O'Connor, Cyndi Lauper, Thomas Dolby, Joni Mitchell, Marianne Faithfull, Levon Helm, Rick Danko and Van Morrison. Over the years, there has been a repeated controversial debate as to whether 9 November would make a suitable German national holiday, often initiated by former members of political opposition in East Germany, such as Werner Schulz. Besides being the emotional apogee of East Germany's peaceful revolution, 9 November is also the date of the 1918 abdication of Kaiser Wilhelm II and declaration of the Weimar Republic, the first German republic.
Sources: en.wikipedia.org
In the field of pharmacokinetics, the area under the curve (AUC) is the definite integral of the concentration of a drug in blood plasma as a function of time (this can be done using liquid chromatography–mass spectrometry). In practice, the drug concentration is measured at certain discrete points in time and the trapezoidal rule is used to estimate AUC. In pharmacology, the area under the plot of plasma concentration of a drug versus time after dosage (called "area under the curve" or AUC) gives insight into the extent of exposure to a drug and its clearance rate from the body.
Thorium-232 is not fissile, but it can undergo fission with high-energy neutrons. Its use in a reactor fuel cycle requires a fissile driver, such as uranium or plutonium, to sustain a chain reaction. However, 232Th is fertile: it can capture a neutron to form 233Th, which undergoes a beta decay with a half-life of 21.8 minutes to 233Pa, then another with a half-life of 27 days to form fissile 233U. Thorium is estimated to be about three to four times as abundant as uranium in Earth's upper crust. Uranium-233 produced in thorium fuel cycles raises proliferation concerns. Radiation from uranium-232 decay products can complicate fuel handling. The risks depend on fuel-cycle design and safeguards. A 1958 report described the Indian Point reactor under construction, with thorium as a fertile material to supplement uranium-235 fuel. The Shippingport light-water breeder reactor core operated with fuel containing uranium-233 and thorium. Thorium-based nuclear power has not seen large-scale commercial use as of 2024. Nevertheless, some countries such as India have actively pursued thorium-based nuclear power. In November 2025, the Chinese Academy of Sciences reported thorium-to-uranium conversion following thorium loading in an experimental molten-salt reactor built by its Shanghai Institute of Applied Physics and partner institutions. The institute stated that it planned a 100-megawatt demonstration project by 2035.
"Neats" hope that intelligent behaviour is described using simple, elegant principles (such as logic or optimisation). "Scruffies" expect that it necessarily requires solving a large number of unrelated problems. Neats defend their programs with theoretical rigour, scruffies rely mainly on incremental testing to see if they work. This issue was actively discussed in the 1970s and 1980s. The rise of deep learning may represent a shift toward the scruffies.
"South Park: The End of Obesity" is a 2024 American adult animated comedy television special episode. It is the seventh South Park television special, and the 328th episode of the series overall. The special premiered on May 24, 2024, on Paramount+. The special satirizes celebrities' glamorized usage of semaglutide-based weight loss drugs and Big Sugar, as well as Lizzo and the inaccessibility of the American health care system.
== Metrology == A number of reference materials are available for silver nanoparticles. NIST RM 8017 contains 75 nm silver nanoparticles embedded in a cake of the polymer polyvinylpyrrolidone to stabilize them against oxidation for a long shelf life. They have reference values for mean particle size using dynamic light scattering, ultra-small-angle X-ray scattering, atomic force microscopy, and transmission electron microscopy; and size distribution reference values for the latter two methods. The BAM-N001 certified reference material contains silver nanoparticles with a specified size distribution with a number-weighted median size of 12.6 nm measured by small-angle X-ray scattering and transmission electron microscopy.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.